# Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)

> **NCT02286063** · PHASE4 · COMPLETED · sponsor: **Royal Brompton & Harefield NHS Foundation Trust** · enrollment: 70 (actual)

## Conditions studied

- Lung; Disease, Fibroid (Chronic)

## Interventions

- **DRUG:** Ambulatory Oxygen

## Key facts

- **NCT ID:** NCT02286063
- **Lead sponsor:** Royal Brompton & Harefield NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02286063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02286063, "Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02286063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*